Cas no 259139-19-0 (3,4-(2',2'-diethylpropylene)dioxythiophene)
3,4-(2',2'-diethylpropylene)dioxythiophene Chemical and Physical Properties
Names and Identifiers
-
- 3,4-(2',2'-diethylpropylene)dioxythiophene
- 3,3-diethyl-2,4-dihydrothieno[3,4-b][1,4]dioxepine
- 3,4-(2′,2′-Diethylpropylene)dioxythiophene
- 2H-Thieno[3,4-b][1,4]dioxepin, 3,3-diethyl-3,4-dihydro-
- 3,3-Diethyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepin
- 3,3-diethyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine
- 3,4-(2 inverted exclamation marka,2 inverted exclamation marka-Diethylpropylene)dioxythiophene
- 3,4-(2,2-diethylpropane-1,3-diyldioxy)thiophene
- 669210_ALDRICH
- AG-E-80360
- AGN-PC-00F3Z8
- CTK0J3698
- SureCN2754120
- J-016176
- 3,4-(2,2-Diethylpropylene)dioxythiophene,97%
- SB67116
- SCHEMBL2754120
- CS-0450451
- 3,3-DIETHYL-2H,4H-THIENO[3,4-B][1,4]DIOXEPINE
- DTXSID90471346
- 259139-19-0
- 3,4-(2',2'-Diethylpropylene)dioxythiophene, 97%
- MFCD08705267
-
- MDL： MFCD08705267
- Inchi： 1S/C11H16O2S/c1-3-11(4-2)7-12-9-5-14-6-10(9)13-8-11/h5-6H,3-4,7-8H2,1-2H3
- InChI Key： HMKHKPKUPVRLOW-UHFFFAOYSA-N
- SMILES： S1C=C2C(=C1)OCC(CO2)(CC)CC
Computed Properties
- Exact Mass: 212.08700
- Monoisotopic Mass: 212.08710092g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 0
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 14
- Rotatable Bond Count: 2
- Complexity: 176
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 3.2
- Topological Polar Surface Area: 46.7?2
Experimental Properties
- Density: 1.109?g/mL?at 25?°C
- Refractive Index: n20/D 1.534
- PSA: 46.70000
- LogP: 3.32570
3,4-(2',2'-diethylpropylene)dioxythiophene Security Information
- Hazardous Material transportation number：NONH for all modes of transport
- WGK Germany：3
3,4-(2',2'-diethylpropylene)dioxythiophene Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd. | 669210-250MG |
3,4-(2',2'-diethylpropylene)dioxythiophene |
259139-19-0 | 250mg |
￥1603.09 | 2023-11-30 | ||
| abcr | AB465731-250 mg |
3,4-(2',2'-Diethylpropylene)dioxythiophene |
259139-19-0 | 250mg |
€469.00 | 2023-04-21 | ||
| abcr | AB465731-1 g |
3,4-(2',2'-Diethylpropylene)dioxythiophene |
259139-19-0 | 1g |
€1,256.40 | 2023-04-21 | ||
| abcr | AB465731-250mg |
3,4-(2',2'-Diethylpropylene)dioxythiophene; . |
259139-19-0 | 250mg |
€178.80 | 2025-03-19 | ||
| abcr | AB465731-1g |
3,4-(2',2'-Diethylpropylene)dioxythiophene; . |
259139-19-0 | 1g |
€362.10 | 2025-03-19 | ||
| Ambeed | A827823-100mg |
3,3-Diethyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine |
259139-19-0 | 95% | 100mg |
$84.0 | 2024-07-28 | |
| Ambeed | A827823-250mg |
3,3-Diethyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine |
259139-19-0 | 95% | 250mg |
$142.0 | 2024-07-28 | |
| Ambeed | A827823-1g |
3,3-Diethyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine |
259139-19-0 | 95% | 1g |
$381.0 | 2024-07-28 | |
| A2B Chem LLC | AB28114-50mg |
2H-Thieno[3,4-b][1,4]dioxepin, 3,3-diethyl-3,4-dihydro- |
259139-19-0 | 97% | 50mg |
$94.00 | 2024-04-20 | |
| A2B Chem LLC | AB28114-1g |
2H-Thieno[3,4-b][1,4]dioxepin, 3,3-diethyl-3,4-dihydro- |
259139-19-0 | 97% | 1g |
$848.00 | 2024-04-20 |
3,4-(2',2'-diethylpropylene)dioxythiophene Related Literature
-
Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
-
Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
-
Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
-
Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
-
Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
Additional information on 3,4-(2',2'-diethylpropylene)dioxythiophene
Recent Advances in the Study of 259139-19-0 and 3,4-(2',2'-Diethylpropylene)dioxythiophene in Chemical Biomedicine
The compound 259139-19-0 and its derivative, 3,4-(2',2'-diethylpropylene)dioxythiophene, have recently garnered significant attention in the field of chemical biomedicine due to their unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on these compounds, focusing on their synthesis, biological activity, and potential applications in drug development and biomedical engineering.
Recent studies have highlighted the role of 259139-19-0 as a key intermediate in the synthesis of novel conjugated polymers, particularly those based on thiophene derivatives. The compound's structural versatility allows for the development of materials with tailored electronic and optical properties, making it a promising candidate for applications in biosensors and drug delivery systems. Concurrently, 3,4-(2',2'-diethylpropylene)dioxythiophene has been investigated for its exceptional conductivity and biocompatibility, which are critical for its use in neural interfaces and tissue engineering scaffolds.
One of the most notable advancements in this area is the successful integration of 3,4-(2',2'-diethylpropylene)dioxythiophene into organic electrochemical transistors (OECTs). These devices have demonstrated remarkable sensitivity in detecting biomolecules, such as glucose and dopamine, at physiologically relevant concentrations. The high stability and low cytotoxicity of this polymer under physiological conditions further underscore its potential for in vivo applications. Additionally, researchers have explored its use in photodynamic therapy, where its ability to generate reactive oxygen species upon light irradiation has shown promise in targeted cancer treatment.
From a synthetic chemistry perspective, novel methodologies have been developed to optimize the production of 259139-19-0 and its derivatives. Recent publications describe improved catalytic systems that enhance yield and purity while reducing environmental impact. These advances are particularly relevant given the growing demand for sustainable pharmaceutical manufacturing processes. Furthermore, computational studies have provided deeper insights into the structure-activity relationships of these compounds, enabling more rational design of derivatives with enhanced biological activity.
The pharmacological potential of these compounds is equally noteworthy. Preclinical studies have demonstrated that certain derivatives exhibit potent anti-inflammatory and neuroprotective effects, suggesting possible applications in treating neurodegenerative disorders. The unique electronic properties of these molecules also make them suitable candidates for developing novel antimicrobial agents, with preliminary data showing activity against drug-resistant bacterial strains.
In conclusion, the ongoing research on 259139-19-0 and 3,4-(2',2'-diethylpropylene)dioxythiophene continues to reveal exciting possibilities at the intersection of chemistry and biomedicine. While significant progress has been made in understanding their properties and potential applications, further studies are needed to fully explore their therapeutic potential and address challenges related to scalability and long-term biocompatibility. The coming years are likely to witness important developments in this field, potentially leading to breakthrough applications in medical diagnostics and treatment.
259139-19-0 (3,4-(2',2'-diethylpropylene)dioxythiophene) Related Products
- 255901-50-9(3,3-Dimethyl-3,4-dihydro-2H-thieno3,4-b1,4dioxepine)
- 634591-75-6(3,3-bis(2-ethylhexyloxymethyl)-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine)
- 125300-69-8(Thiophene,3-[(2-ethylhexyl)oxy]-)
- 259139-23-6(3,3-Dioctyl-3,4-dihydro-2H-thieno[3,4-b][1,4]dioxepine)
- 700816-98-4(2H-Thieno[3,4-b][1,4]dioxepin, 3,3-dihexyl-3,4-dihydro-)
- 156112-75-3(Thiophene, 3,4-bis(decyloxy)-)
- 211235-81-3(Thiophene, 3,4-bis(hexyloxy)-)
- 207802-19-5(Thiophene, 3,4-bis(octyloxy)-)
- 496800-96-5(Thiophene, 3,4-bis(dodecyloxy)-)
- 918536-90-0(2H-Thieno[3,4-b][1,4]dioxepin, 3,3-bis[(hexyloxy)methyl]-3,4-dihydro-)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
